<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03184376</url>
  </required_header>
  <id_info>
    <org_study_id>E-23936</org_study_id>
    <nct_id>NCT03184376</nct_id>
  </id_info>
  <brief_title>Histological Improvement of NASH With Prebiotic</brief_title>
  <official_title>Histological Improvement of Non-alcoholic Steatohepatitis With a Prebiotic: a Pilot Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will investigate the therapeutic potential of a prebiotic supplement to improve
      histological parameters of NASH. In a single-blind, placebo controlled, randomized pilot
      trial will be conduced in individuals with liver biopsy confirmed NASH (Non-alcoholic fatty
      liver activity score (NAS) â‰¥ 5). Participants will be randomized to receive oligofructose (8
      g/day for 12 weeks and 16g/day for 24 weeks) or isocaloric placebo for 9 months. The primary
      outcome measure is the change in liver biopsy NAS score and the secondary outcomes include
      changes in body weight, body composition, glucose tolerance, serum lipids, inflammatory
      markers, and gut microbiota.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oligofructose and maltodextrin are both white powders that taste and look the same. They were
      both package in individual foil packets. Participants were blinded to the treatment
      allocation. Adherence to supplement protocol was monitored throughout the study through
      direct questioning and counting unused supplement packages. Participants were asked to
      maintain their usual physical activity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 28, 2012</start_date>
  <completion_date type="Actual">May 30, 2016</completion_date>
  <primary_completion_date type="Actual">December 16, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single-blind, placebo controlled, randomized trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participants were blinded to the treatment allocation. Oligofructose and maltodextrin taste and look the same (white powder) and both were placed in identical foil packaging.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Histological change</measure>
    <time_frame>9 months</time_frame>
    <description>Nonalcoholic fatty liver disease activity score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>9 months</time_frame>
    <description>Body lean and fat mass</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>9 months</time_frame>
    <description>Body weight measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose tolerance</measure>
    <time_frame>9 months</time_frame>
    <description>Oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut microbiota</measure>
    <time_frame>9 months</time_frame>
    <description>Intestinal microbiota composition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum total cholesterol</measure>
    <time_frame>9 months</time_frame>
    <description>Total cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum LDL cholesterol</measure>
    <time_frame>9 months</time_frame>
    <description>Low-density lipoprotein cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum triglycerides</measure>
    <time_frame>9 months</time_frame>
    <description>Triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum HDL cholesterol</measure>
    <time_frame>9 months</time_frame>
    <description>High-density lipoprotein cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum IL-6</measure>
    <time_frame>9 months</time_frame>
    <description>Interleukin-6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum TNF-alpha</measure>
    <time_frame>9 months</time_frame>
    <description>Tumor necrosis factor - alpha</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Prebiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prebiotic oligofructose (Orafti P95, Beneo-Orafti Inc., Tienen, Belgium) taken 8g orally per day for 12 weeks followed by 16g per day for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo maltodextrin (isocaloric to prebiotic) taken 3.3g orally per day for 12 weeks followed by 6.6g per day for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Prebiotic oligofructose</intervention_name>
    <description>Powder format</description>
    <arm_group_label>Prebiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo maltodextrin</intervention_name>
    <description>Powder format</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Liver biopsy confirmed NASH (NAS score greater than or equal to 5)

          -  BMI &gt;25 kg/m2 (Caucasians)

          -  &gt;23 kg/m2 (Asians)

          -  History of Serum ALT &gt;1.5X upper normal limit

          -  No changes in lipid-lowering or diabetes medication over previous three months

          -  Ability to provide informed consent

        Exclusion Criteria:

          -  alcohol consumption &gt;20g/day (women) or &gt;30g/day (men)

          -  alternate etiology for abnormal liver enzymes

          -  decompensated liver disease

          -  use of orlistat, liraglutide, prebiotic, probiotic, or antibiotic within 3 months
             prior to enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raylene A Reimer, PhD, RD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Calgary</affiliation>
  </overall_official>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2017</study_first_submitted>
  <study_first_submitted_qc>June 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2017</study_first_posted>
  <last_update_submitted>June 9, 2017</last_update_submitted>
  <last_update_submitted_qc>June 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Calgary</investigator_affiliation>
    <investigator_full_name>Dr. Raylene Reimer</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Gut microbiota</keyword>
  <keyword>Prebiotic</keyword>
  <keyword>Liver biopsy</keyword>
  <keyword>Oligofructose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Other researchers would need to make an individual inquiry.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

